Combining compounds is the hard part

Six injectable peptides on a six-month alternating active/maintenance protocol that cycles immune activation and longevity signalling while keeping regenerative support continuous. Built on the KLOW backbone — a copper tripeptide, two regenerative peptides and an anti-inflammatory tripeptide — with thymic immune modulation added, and a pineal tetrapeptide that appears in the first vial only. That alternation is deliberate: research describes continuous dosing of that compound as potentially downregulating the pathway it acts on, so the two-vial structure enforces the cycling rather than trusting anyone to remember it.

An NAD+ precursor paired with the bioactive form of B12, dosed three times weekly. Revised in July 2026: direct NAD+ was removed entirely and the precursor load raised, because research describes the precursor converting in vivo with high reported efficiency — carrying both was largely redundant, and dropping one removed the component with the tightest pH constraint. The B12 is not an additive; published work describes precursor metabolism as consuming methyl groups, so it is there to cover what the primary active spends.

The Wolverine stack taken seriously. Almost everyone running peptides for injury ends up on the same two — BPC-157 and Thymosin β-4 — and the pairing works, which is why it is worth asking what it is missing. This is that stack at roughly four times the commonly cited dose, built with the full-length 43-amino-acid molecule rather than the seven-residue fragment most vendors ship as 'TB-500', with two growth hormone secretagogues added on separate receptors. What the original pairing never had is the systemic repair signal: it acts on the site without changing the hormonal environment the site is repairing in. Dosed at bedtime so it arrives alongside the body's own largest nightly GH pulse.

A daily mitochondrial stack where both actives aim at the same thing: energy. 5-Amino-1MQ inhibits NNMT, an enzyme research describes as continuously consuming NAD+ precursors and methyl donors to make a metabolic dead-end product — and as elevated in aged adipose tissue and obese muscle, so the people with the least metabolic headroom run the largest version of the leak. MOTS-c is a peptide the mitochondria encode themselves, described as an exercise signal acting through AMPK and PGC-1α. One stops the waste, the other builds the capacity to spend it. Neither is a stimulant, and what users report is not a lift — it is the absence of the drop.

Formerly SuperBURN — renamed because the name was writing cheques the formula does not cash. Two capsules deliver 200 mg of caffeine matched one-to-one with L-theanine, 300 mg of rhodiola, glycine and a B-complex: clean alertness without the edge, and no afternoon cliff. What makes it unusual is the 5-Amino-1MQ underneath — an NNMT inhibitor, where research describes the enzyme as consuming a NAD+ precursor and a methyl donor in the same reaction, so inhibiting it spares both pools at once. The niacinamide is deliberately held low: it feeds the salvage pathway the inhibitor protects, and more would work against the sirtuin side. An energy and focus capsule with a real metabolic active — not a thermogenic, and we will not call it one.

The usual approach to a women's version of anything in this category is to keep the formula and change the label. This differs in four substantive ways. One peptide is removed entirely — a small number of female users report emotional blunting on BPC-157, and we would rather formulate around a risk we cannot rule out than argue with the people describing it. Thymic peptide is doubled, to a weekly exposure set alongside the clinical dose, because research describes thymic decline as accelerating at menopause. And two compounds are added specifically because the evidence behind them was female: a GHRH analogue at exactly the dose and route used in a cognitive trial whose cohort was 59% women, and a mitochondrial peptide reported to prevent both obesity and insulin resistance in the experimental model of menopause.

For the GLP-1 side effect that gets discussed far less than the nausea, and that in our experience is the one that makes people quit: orgasm becoming delayed, muted or absent. The first published case report attributing it to GLP-1 therapy puts the mechanism at reduced hypothalamic dopamine and norepinephrine signalling — the same reward pathway the appetite suppression works through. Dopaminergic signalling fails in two places here, so this addresses both: a melanocortin agonist that drives central dopamine release through a pathway the GLP-1 is not suppressing, and a positive allosteric modulator that makes D2/D4 receptors more responsive to whatever arrives. That second compound cannot activate a receptor on its own — it has no effect until your own dopamine shows up, which is why the literature does not describe it with the compulsion profile of direct agonists. The usual advice is to cut the dose and accept losing ground. This addresses the mechanism instead.